PMID- 12782326
OWN - NLM
STAT- MEDLINE
DCOM- 20030707
LR  - 20190621
IS  - 0014-5793 (Print)
IS  - 0014-5793 (Linking)
VI  - 544
IP  - 1-3
DP  - 2003 Jun 5
TI  - Anti-angiogenic property of edible berry in a model of hemangioma.
PG  - 252-7
AB  - Hemangiomas represent a powerful model to study in vivo angiogenesis. Monocyte 
      chemotactic protein 1 (MCP-1) is known to be responsible for recruiting 
      macrophages to sites of infection or inflammation and facilitate angiogenesis. 
      Recently we have demonstrated that edible berry extracts potently suppress 
      inducible vascular endothelial growth factor expression and in vitro 
      angiogenesis. Comparative analysis of several berry extracts led to the 
      observation that wild blueberry and a berry mix were most effective. Our goal was 
      to follow up on our findings with wild blueberry and the berry mix (OptiBerry). 
      The present work rests on our current finding that these two berry powders 
      significantly inhibit inducible MCP-1 expression in endothelioma cells. 
      Therefore, we sought to examine the effects of wild blueberry and berry mix in an 
      in vivo model of experimental angiogenesis. Reporter studies showed that the 
      berry powders significantly inhibited basal MCP-1 transcription and inducible 
      nuclear factor kappaB transcription. Endothelioma cells pre-treated with berry 
      powders showed diminished ability to form hemangioma. Histological analysis 
      demonstrated markedly decreased infiltration of macrophages in hemangioma of 
      treated mice compared to placebo-treated controls. The current results provide 
      the first in vivo evidence substantiating the anti-angiogenic property of edible 
      berries.
FAU - Atalay, Mustafa
AU  - Atalay M
AD  - Laboratory of Molecular Medicine, Department of Surgery, 512 Dorothy M. Davis 
      Heart and Lung Research Institute, The Ohio State University Medical Center, 473 
      W. 12th Avenue, Columbus 43210, USA.
FAU - Gordillo, Gayle
AU  - Gordillo G
FAU - Roy, Sashwati
AU  - Roy S
FAU - Rovin, Brad
AU  - Rovin B
FAU - Bagchi, Debasis
AU  - Bagchi D
FAU - Bagchi, Manashi
AU  - Bagchi M
FAU - Sen, Chandan K
AU  - Sen CK
LA  - eng
GR  - GM27345/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - FEBS Lett
JT  - FEBS letters
JID - 0155157
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antioxidants)
RN  - 0 (Autoantigens)
RN  - 0 (Ccl2 protein, mouse)
RN  - 0 (Chemokine CCL2)
RN  - 0 (NF-kappa B)
RN  - 0 (Plant Extracts)
RN  - EC 1.13.12.- (Luciferases)
SB  - IM
MH  - Angiogenesis Inhibitors/*pharmacology
MH  - Animals
MH  - Antioxidants/pharmacology
MH  - Autoantigens/biosynthesis
MH  - Blueberry Plants
MH  - Cell Survival
MH  - *Chemokine CCL2
MH  - Dose-Response Relationship, Drug
MH  - Endothelium/drug effects
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Flow Cytometry
MH  - Fruit
MH  - Genes, Reporter
MH  - Hemangioma/*drug therapy
MH  - Immunohistochemistry
MH  - Luciferases/metabolism
MH  - Mice
MH  - NF-kappa B/metabolism
MH  - Plant Extracts/*pharmacology
MH  - Time Factors
MH  - Tumor Cells, Cultured
EDAT- 2003/06/05 05:00
MHDA- 2003/07/08 05:00
CRDT- 2003/06/05 05:00
PHST- 2003/06/05 05:00 [pubmed]
PHST- 2003/07/08 05:00 [medline]
PHST- 2003/06/05 05:00 [entrez]
AID - S001457930300509X [pii]
AID - 10.1016/s0014-5793(03)00509-x [doi]
PST - ppublish
SO  - FEBS Lett. 2003 Jun 5;544(1-3):252-7. doi: 10.1016/s0014-5793(03)00509-x.